SALMETEROL XINAFOATE vs UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

Compare SALMETEROL XINAFOATE (SEREVENT DISKUS) and UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE (Anoro Ellipta) — clinical data, side effects, and patient experiences.

SALMETEROL XINAFOATE

SEREVENT DISKUS · Beta-2 Agonist Bronchodilator

How it works

12.1 Mechanism of Action Salmeterol is a selective LABA. In vitro studies show salmeterol to be at least 50 times more selective for beta 2 -adrenoceptors than albuterol. Although ...

Approved for

including patients with symptoms of nocturnal asthma. LABA

such as salmeterol

the active ingredient in SEREVENT DISKUS

appropriate steps must be taken to ensure adherence with both treatment components. If adherence cannot be assured

Oral, Respiratory (inhalation)Tablet

UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

Anoro Ellipta · Beta-2 Agonist Bronchodilator

How it works

12.1 Mechanism of Action ANORO ELLIPTA ANORO ELLIPTA contains both umeclidinium and vilanterol. The mechanisms of action described below for the individual components apply to ANOR...

Approved for

an anticholinergic

and vilanterol

a long-acting beta 2 -adrenergic agonist (LABA)

5.2 )

Respiratory (inhalation)Tablet

Quick Comparison

SALMETEROL XINAFOATEUMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

Drug Class

Beta-2 Agonist Bronchodilator

Route

Oral, Respiratory (inhalation)

Respiratory (inhalation)

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

SALMETEROL XINAFOATE

Shortness of Breath

>10%

Drug Not Working

>10%

Cough

1-10%

Fatigue

1-10%

General Unwellness

1-10%

Headache

0.1-1%

Nausea

0.1-1%

Dizziness

0.1-1%

UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

Shortness of Breath

>10%

Drug Not Working

>10%

Cough

1-10%

Fatigue

0.1-1%

Headache

0.1-1%

Condition Worsened

0.1-1%

FDA Warnings

SALMETEROL XINAFOATE

5 WARNINGS AND PRECAUTIONS • LABA as monotherapy (without ICS) for asthma increase the risk of asthma-related death and asthma-related hospitalizations
3 ) • Do not use in combination with an additional medicine containing a LABA because of risk of overdose
1 Asthma-Related Death LABA, such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without ICS) increase the risk of asthma-related death
When LABA are used in fixed - dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone

UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

5 WARNINGS AND PRECAUTIONS • LABA monotherapy (without an inhaled corticosteroid) for asthma increases the risk of serious asthma-related events
2 ) • Do not use in combination with additional therapy containing a LABA because of risk of overdose
1 Serious Asthma-Related Events – Hospitalizations, Intubations, Death The safety and effectiveness of ANORO ELLIPTA in patients with asthma have not been established
Use of LABA as monotherapy (without ICS) for asthma is associated with an increased risk of asthma-related death

Clinical Trial Data

No head-to-head clinical studies found for SALMETEROL XINAFOATE vs UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE.

SALMETEROL XINAFOATE vs UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE: What You Should Know

Key Differences

Both SALMETEROL XINAFOATE and UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE belong to the Beta-2 Agonist Bronchodilator class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. SALMETEROL XINAFOATE is administered via Oral or Respiratory (inhalation), whereas UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE uses Respiratory (inhalation). Route of administration can affect onset of action and patient adherence.

Safety Considerations

SALMETEROL XINAFOATE carries 4 FDA warnings. UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

FORMOTEROL FUMARATE vs SALMETEROL XINAFOATE→ALBUTEROL vs SALMETEROL XINAFOATE→LEVALBUTEROL HYDROCHLORIDE vs SALMETEROL XINAFOATE→FORMOTEROL FUMARATE DIHYDRATE vs SALMETEROL XINAFOATE→SALMETEROL XINAFOATE vs TIOTROPIUM BROMIDE AND OLODATEROL→FLUTICASONE PROPIONATE AND SALMETEROL vs SALMETEROL XINAFOATE→

Loading comparison data...

SALMETEROL XINAFOATE vs UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

Compare SALMETEROL XINAFOATE (SEREVENT DISKUS) and UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE (Anoro Ellipta) — clinical data, side effects, and patient experiences.

SALMETEROL XINAFOATE

SEREVENT DISKUS · Beta-2 Agonist Bronchodilator

How it works

12.1 Mechanism of Action Salmeterol is a selective LABA. In vitro studies show salmeterol to be at least 50 times more selective for beta 2 -adrenoceptors than albuterol. Although ...

Approved for

including patients with symptoms of nocturnal asthma. LABA

such as salmeterol

the active ingredient in SEREVENT DISKUS

appropriate steps must be taken to ensure adherence with both treatment components. If adherence cannot be assured

Oral, Respiratory (inhalation)Tablet

UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

Anoro Ellipta · Beta-2 Agonist Bronchodilator

How it works

12.1 Mechanism of Action ANORO ELLIPTA ANORO ELLIPTA contains both umeclidinium and vilanterol. The mechanisms of action described below for the individual components apply to ANOR...

Approved for

an anticholinergic

and vilanterol

a long-acting beta 2 -adrenergic agonist (LABA)

5.2 )

Respiratory (inhalation)Tablet

Quick Comparison

SALMETEROL XINAFOATEUMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

Drug Class

Beta-2 Agonist Bronchodilator

Route

Oral, Respiratory (inhalation)

Respiratory (inhalation)

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

SALMETEROL XINAFOATE

Shortness of Breath

>10%

Drug Not Working

>10%

Cough

1-10%

Fatigue

1-10%

General Unwellness

1-10%

Headache

0.1-1%

Nausea

0.1-1%

Dizziness

0.1-1%

UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

Shortness of Breath

>10%

Drug Not Working

>10%

Cough

1-10%

Fatigue

0.1-1%

Headache

0.1-1%

Condition Worsened

0.1-1%

FDA Warnings

SALMETEROL XINAFOATE

5 WARNINGS AND PRECAUTIONS • LABA as monotherapy (without ICS) for asthma increase the risk of asthma-related death and asthma-related hospitalizations
3 ) • Do not use in combination with an additional medicine containing a LABA because of risk of overdose
1 Asthma-Related Death LABA, such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without ICS) increase the risk of asthma-related death
When LABA are used in fixed - dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone

UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE

5 WARNINGS AND PRECAUTIONS • LABA monotherapy (without an inhaled corticosteroid) for asthma increases the risk of serious asthma-related events
2 ) • Do not use in combination with additional therapy containing a LABA because of risk of overdose
1 Serious Asthma-Related Events – Hospitalizations, Intubations, Death The safety and effectiveness of ANORO ELLIPTA in patients with asthma have not been established
Use of LABA as monotherapy (without ICS) for asthma is associated with an increased risk of asthma-related death

Clinical Trial Data

No head-to-head clinical studies found for SALMETEROL XINAFOATE vs UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE.

SALMETEROL XINAFOATE vs UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.